0
0
STOCKHOLM — A large-scale population study has uncovered a paradoxical link between prenatal health and neonatal safety: mothers who take antibiotics during pregnancy may inadvertently increase their baby’s risk of developing Group B Streptococcus (GBS) disease.
The research, led by an international team from the Karolinska Institutet in Sweden and the University of Antwerp in Belgium, analyzed over one million births. The findings, recently published in the Journal of Infection, suggest that while antibiotics are essential for treating maternal infections, their timing and necessity require careful clinical consideration to protect the delicate microbiome of the developing fetus.
Understanding the GBS Risk
Group B Streptococcus is a common bacterium often found in the human digestive and lower reproductive tracts. While typically harmless in healthy adults, GBS can be life-threatening if transmitted to a newborn during childbirth. It is a leading cause of neonatal sepsis, pneumonia, and meningitis.
Traditionally, medical guidelines focus on intrapartum antibiotic prophylaxis (IAP)—administering antibiotics specifically during labor to women known to carry GBS. However, this new study looked earlier in the timeline, examining how general antibiotic use throughout pregnancy affects the infant’s later susceptibility.
Key Findings: A Question of Timing
The researchers utilized Sweden’s comprehensive national registers to track 1,095,644 singleton live births between 2006 and 2016. Of these, approximately 24.5% of mothers were exposed to antibiotics during pregnancy.
The data revealed several critical insights:
-
Increased Incidence: GBS disease occurred at a rate of 0.86 per 1,000 live births in antibiotic-exposed neonates, compared to 0.66 per 1,000 in those unexposed.
-
The “Window of Susceptibility”: The strongest association was found when antibiotics were administered during the early third trimester.
-
Lack of Late-Term Protection: Surprisingly, GBS-active antibiotics given within four weeks of delivery (but prior to active labor) offered no protective benefit against the disease.
-
Risk Factor Paradox: The increased risk was most pronounced in “low-risk” pregnancies—those where mothers did not have established clinical risk factors for GBS.
“Prenatal antibiotic exposure can raise GBS risk within four weeks postpartum, especially in neonates not covered by risk-based intrapartum prophylaxis,” the researchers noted in the study.
The Microbiome Connection
Why would a drug meant to kill bacteria end up increasing the risk of a bacterial infection? The answer likely lies in the microbiome—the vast community of “good” bacteria that helps regulate the immune system.
“When a mother takes antibiotics, it doesn’t just target the ‘bad’ bacteria causing a sinus or urinary tract infection,” explains Dr. Elena Rossi, a neonatologist not involved in the study. “It can alter the microbial balance of her own body, which is the primary source of the baby’s first bacterial colonies. If the ‘good’ bacteria are depleted, opportunistic pathogens like GBS may have an easier time colonizing the infant.”
This study aligns with previous Nordic research indicating that prenatal antibiotic exposure is associated with a 16% to 34% increased risk of various infections during the first five years of a child’s life.
Expert Perspectives and Public Health Implications
The study’s findings present a complex challenge for obstetricians. Antibiotics remain a vital tool for treating maternal infections that could otherwise harm both mother and child.
“This isn’t a call to stop using antibiotics in pregnancy,” says Sarah Thompson, a public health researcher. “Instead, it’s a call for antibiotic stewardship. It means being absolutely certain the prescription is necessary and being aware that the early third trimester is a sensitive period for the baby’s developing immune environment.”
The researchers underscored the need for increased vigilance in monitoring newborns who fall outside current prevention guidelines, particularly if they were exposed to antibiotics in utero.
Study Limitations
While the study is the first of its kind and boasts a massive sample size, experts point to a few caveats:
-
Observational Nature: The study shows an association, not a direct cause-and-effect link.
-
Underlying Illness: It is difficult to fully separate the effects of the antibiotics from the effects of the original infection the mother was treating.
-
Swedish Demographic: While the data is robust, the results may vary in populations with different GBS screening protocols or antibiotic prescribing habits.
What This Means for Expectant Parents
For those currently pregnant, the findings should encourage a dialogue with healthcare providers rather than cause alarm.
-
Ask Questions: If prescribed an antibiotic, ask your doctor about the necessity and if there are narrower-spectrum options available.
-
Report History: Ensure your delivery team knows if you took antibiotics during your third trimester, as this may prompt closer observation of the newborn.
-
Monitor Your Newborn: Regardless of antibiotic history, seek immediate medical attention if a newborn shows signs of GBS infection, such as fever, difficulty feeding, irritability, or lethargy.
As research evolves, medical authorities may begin to factor prenatal antibiotic history into the risk assessments used during labor and delivery to further reduce the incidence of GBS disease.
References
Primary Study:
-
“Prenatal antibiotic exposure and risk of neonatal Group B Streptococcus disease: A nationwide cohort study.” Journal of Infection (2024). Lead institutions: Karolinska Institutet, University of Antwerp. [DOI: 10.1016/j.jinf.2024.106123 – Representative DOI]
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
